Related references
Note: Only part of the references are listed.A PALB2 truncating mutation: Implication in cancer prevention and therapy of Hereditary Breast and Ovarian Cancer
Carolina Velazquez et al.
BREAST (2019)
MRN (MRE11-RAD50-NBS1) Complex in Human Cancer and Prognostic Implications in Colorectal Cancer
Yiling Situ et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Patterns of Genomic Instability in Breast Cancer
Murugan Kalimutho et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2019)
Androgen blockade based clinical trials landscape in triple negative breast cancer
Yaqin Shi et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2018)
Mutant p53 in breast cancer: potential as a therapeutic target and biomarker
Michael J. Duffy et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
BRCA1/2 testing: therapeutic implications for breast cancer management
Nadine M. Tung et al.
BRITISH JOURNAL OF CANCER (2018)
Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007
Naoise C. Synnott et al.
CANCER LETTERS (2018)
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
L. Gerratana et al.
CANCER TREATMENT REVIEWS (2018)
Ataxia-telangiectasia gene (ATM) mutation heterozygosity in breast cancer: a narrative review
K. J. Jerzak et al.
CURRENT ONCOLOGY (2018)
Recent Advances in the Treatment of Breast Cancer
Christy W. S. Tong et al.
FRONTIERS IN ONCOLOGY (2018)
Overexpression of the MRE11-RAD50-NBS1 (MRN) complex in rectal cancer correlates with poor response to neoadjuvant radiotherapy and prognosis
Vincent Ho et al.
BMC CANCER (2018)
Cancer genetics, precision prevention and a call to action
Clare Turnbull et al.
NATURE GENETICS (2018)
The Androgen Receptor in Breast Cancer
Pia Giovannelli et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Novel molecular insights and new therapeutic strategies in osteosarcoma
Babak Otoukesh et al.
CANCER CELL INTERNATIONAL (2018)
BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer
Nana Weber-Lassalle et al.
BREAST CANCER RESEARCH (2018)
Genetic Modifiers of the Breast Tumor Microenvironment
Michael J. Flister et al.
TRENDS IN CANCER (2018)
RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Non-small Cell Lung Cancer
Yifan Wang et al.
CLINICAL CANCER RESEARCH (2018)
BRCA1-Mutated Estrogen Receptor-Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency
Esther H. Lips et al.
CLINICAL CANCER RESEARCH (2017)
Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
N. C. Synnott et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors
Cristina Saura et al.
CANCER DISCOVERY (2017)
The Role of PALB2 in the DNA Damage Response and Cancer Predisposition
Thales C. Nepomuceno et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Coupling of Homologous Recombination and the Checkpoint by ATR
Remi Buisson et al.
MOLECULAR CELL (2017)
Association analysis identifies 65 new breast cancer risk loci
Kyriaki Michailidou et al.
NATURE (2017)
Integrative clinical genomics of metastatic cancer
Dan R. Robinson et al.
NATURE (2017)
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer
Roger L. Milne et al.
NATURE GENETICS (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Combined treatment using the anti-p53 drug, APR-246 and eribulin: Synergistic growth inhibition in p53-mutated breast cancer cells.
Naoise C. Synnott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
George Somlo et al.
CLINICAL CANCER RESEARCH (2017)
A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes
Saundra S. Buys et al.
CANCER (2017)
Targeted therapies in breast cancer: New challenges to fight against resistance
Viviana Masoud et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2017)
Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer
Simone Brandt et al.
BMC CANCER (2017)
A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)
H. Bonnefoi et al.
ANNALS OF ONCOLOGY (2016)
High Expression of MRE11-RAD50-NBS1 Is Associated with Poor Prognosis and Chemoresistance in Gastric Cancer
Bolag Altan et al.
ANTICANCER RESEARCH (2016)
Novel insights into RAD51 activity and regulation during homologous recombination and DNA replication
Stephen K. Godin et al.
BIOCHEMISTRY AND CELL BIOLOGY (2016)
PARP inhibitors: the race is on
Jessica S. Brown et al.
BRITISH JOURNAL OF CANCER (2016)
The therapeutic potential of mTOR inhibitors in breast cancer
Linda S. Steelman et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
BARD1 splice variants display mislocalization in breast cancer cells and can alter the apoptotic response to cisplatin
Kamila A. Marzec et al.
CANCER LETTERS (2016)
Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer
Weimin Li et al.
CLINICAL CANCER RESEARCH (2016)
Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline
N. J. H. van Os et al.
CLINICAL GENETICS (2016)
Targeting the androgen receptor in triple-negative breast cancer
Ayca Gucalp et al.
CURRENT PROBLEMS IN CANCER (2016)
Androgen receptor signaling pathways as a target for breast cancer treatment
Elisabetta Pietri et al.
ENDOCRINE-RELATED CANCER (2016)
CDH1 germline mutations and hereditary lobular breast cancer
Giovanni Corso et al.
FAMILIAL CANCER (2016)
New concepts on BARD1: Regulator of BRCA pathways and beyond
Irmgard Irminger-Finger et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2016)
Molecular Classification of Triple-Negative Breast Cancer
Sung Gwe Ahn et al.
JOURNAL OF BREAST CANCER (2016)
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
Lisa A. Carey et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing
Douglas F. Easton et al.
JOURNAL OF MEDICAL GENETICS (2016)
ATM Mutations in Cancer: Therapeutic Implications
Michael Choi et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170
Alison M. Dunning et al.
NATURE GENETICS (2016)
Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer
Fergus J. Couch et al.
NATURE COMMUNICATIONS (2016)
RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy
Adrian P. Wiegmans et al.
ONCOTARGET (2016)
COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo
Kowthar Y. Salim et al.
ONCOTARGET (2016)
Inherited Mutations in Women With Ovarian Carcinoma
Barbara M. Norquist et al.
JAMA ONCOLOGY (2016)
Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon Cancer
Ozkan Ozden et al.
SCIENTIFIC REPORTS (2016)
The kinome 'at large' in cancer
Emmy D. G. Fleuren et al.
NATURE REVIEWS CANCER (2016)
Hereditary breast and ovarian cancer: new genes in confined pathways
Finn Cilius Nielsen et al.
NATURE REVIEWS CANCER (2016)
Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer
Yin Liu et al.
BMC CANCER (2015)
Nuclear factor I-C regulates E-cadherin via control of KLF4 in breast cancer
Hye-Kyung Lee et al.
BMC CANCER (2015)
Germline TP53 mutational spectrum in French Canadians with breast cancer
Suzanna L. Arcand et al.
BMC Medical Genetics (2015)
Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway
Sharon T. Wilks
BREAST (2015)
Oxidative stress shapes breast cancer phenotype through chronic activation of ATM-dependent signaling
Merve Alpay et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Targeting LKB1 in cancer - exposing and exploiting vulnerabilities
M. Momcilovic et al.
BRITISH JOURNAL OF CANCER (2015)
Notch signaling: An emerging therapeutic target for cancer treatment
Xun Yuan et al.
CANCER LETTERS (2015)
Mechanisms of lapatinib resistance in HER2-driven breast cancer
Valentina D'Amato et al.
CANCER TREATMENT REVIEWS (2015)
Structural perspective of ARHI mediated inhibition of STAT3 signaling: An insight into the inactive to active transition of ARHI and its interaction with STAT3 and importinβ
Kannan Muthu et al.
CELLULAR SIGNALLING (2015)
Effectiveness of Targeted Therapy in Patients With Previously Untreated Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
Pawel Kawalec et al.
CLINICAL BREAST CANCER (2015)
Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells
Pang-ning Teng et al.
GYNECOLOGIC ONCOLOGY (2015)
Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers
Mieke Kriege et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2015)
Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers
Rachel S. van der Post et al.
JOURNAL OF MEDICAL GENETICS (2015)
Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer
Susan J. Ramus et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor
Noa Efrat Ben-Baruch et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2015)
A mechanism for the suppression of homologous recombination in G1 cells
Alexandre Orthwein et al.
NATURE (2015)
Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies
Ines de Paula Costa Monteiro et al.
PHARMACOGENOMICS (2015)
ATM and ATR as therapeutic targets in cancer
Anika Maria Weber et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Better Together: Targeted Combination Therapies in Breast Cancer
Elisa Zanardi et al.
SEMINARS IN ONCOLOGY (2015)
HER2-directed therapy: current treatment options for HER2-positive breast cancer
Shahid Ahmed et al.
BREAST CANCER (2015)
Expression of androgen receptor splice variants in clinical breast cancers
Theresa E. Hickey et al.
ONCOTARGET (2015)
Analysis of large mutations in BARD1 in patients with breast and/or ovarian cancer: the Polish population as an example
Katarzyna Klonowska et al.
SCIENTIFIC REPORTS (2015)
Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer
Susan J. Ramus et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Genetic evaluation based on family history and Her2 status correctly identifies TP53 mutations in very early onset breast cancer cases
F. Fostira et al.
CLINICAL GENETICS (2015)
A Synthetic Lethal Screen Reveals Enhanced Sensitivity to ATR Inhibitor Treatment in Mantle Cell Lymphoma with ATM Loss-of-Function
Daniel L. Menezes et al.
MOLECULAR CANCER RESEARCH (2015)
Trapping Poly(ADP-Ribose) Polymerase
Yuqiao Shen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Lobular breast cancer: incidence and genetic and non-genetic risk factors
Laure Dossus et al.
BREAST CANCER RESEARCH (2015)
Identification of a new BRCA2 large genomic deletion associated with high risk male breast cancer
Ana Rafaela de Souza Timoteo et al.
HEREDITARY CANCER IN CLINICAL PRACTICE (2015)
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
J-m. Lee et al.
ANNALS OF ONCOLOGY (2014)
Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors
J. Balmana et al.
ANNALS OF ONCOLOGY (2014)
Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
Christopher Bryant et al.
BMC CANCER (2014)
Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy
M. Kriege et al.
BRITISH JOURNAL OF CANCER (2014)
dCharacteristics of Individuals With Breast Cancer Rearrangements in BRCA1 and BRCA2
Sarah A. Jackson et al.
CANCER (2014)
Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression
Chunxiao Xu et al.
CANCER CELL (2014)
Abstract 2348: Discovery of AZD6738, a potent and selective inhibitor with the potential to test the clinical efficacy of ATR kinase inhibition in cancer patients.
Clifford D. Jones et al.
CANCER RESEARCH (2014)
Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines
Eiji Kubota et al.
CELL CYCLE (2014)
Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
Kathryn P. Pennington et al.
CLINICAL CANCER RESEARCH (2014)
TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance
Laxmi Silwal-Pandit et al.
CLINICAL CANCER RESEARCH (2014)
Targeting the LKB1 Tumor Suppressor
Rui-Xun Zhao et al.
CURRENT DRUG TARGETS (2014)
Therapeutic Targeting of Cancers with Loss of PTEN Function
Lloye M. Dillon et al.
CURRENT DRUG TARGETS (2014)
The Mre11/Rad50/Nbs1 complex: Recent insights into catalytic activities and ATP-driven conformational changes
Tanya T. Paull et al.
EXPERIMENTAL CELL RESEARCH (2014)
Mutant p53 reactivation by small molecules makes its way to the clinic
Vladimir J. N. Bykov et al.
FEBS LETTERS (2014)
Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium
Roger L. Milne et al.
HUMAN MOLECULAR GENETICS (2014)
Germline TP53 Mutations and the Changing Landscape of Li-Fraumeni Syndrome
Junne Kamihara et al.
HUMAN MUTATION (2014)
Breast cancer adaptive resistance: HER2 and cancer stem cell repopulation in a heterogeneous tumor society
Nadire Duru et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)
Loss of LKB1 disrupts breast epithelial cell polarity and promotes breast cancer metastasis and invasion
Juan Li et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2014)
Revising the role of the androgen receptor in breast cancer
F. M. Fioretti et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2014)
Therapeutic Targeting of Integrin αvβ6 in Breast Cancer
Kate M. Moore et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Nadia Howlader et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
Mari Iida et al.
MOLECULAR CANCER (2014)
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2014)
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Jonathan Ledermann et al.
LANCET ONCOLOGY (2014)
Comprehensive molecular characterization of urothelial bladder carcinoma
John N. Weinstein et al.
NATURE (2014)
Breast-Cancer Risk in Families with Mutations in PALB2
A. C. Antoniou et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario
Marta Bonotto et al.
ONCOLOGIST (2014)
A Small Molecule Inhibitor of Human RAD51 Potentiates Breast Cancer Cell Killing by Therapeutic Agents in Mouse Xenografts
Fei Huang et al.
PLOS ONE (2014)
Effect of MRE11 Loss on PARP-Inhibitor Sensitivity in Endometrial Cancer In Vitro
Romana Koppensteiner et al.
PLOS ONE (2014)
Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation
Pierluigi Gasparini et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Two Decades After BRCA: Setting Paradigms in Personalized Cancer Care and Prevention
Fergus J. Couch et al.
SCIENCE (2014)
Rad51 supports triple negative breast cancer metastasis
Adrian P. Wiegmans et al.
ONCOTARGET (2014)
Imaging preclinical tumour models: improving translational power
Marion de Jong et al.
NATURE REVIEWS CANCER (2014)
Phase I trial of the PARP inhibitor veliparib (V) in combination with carboplatin (C) in metastatic breast cancer (MBC).
Robert Wesolowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells
Edmund Chinchar et al.
VASCULAR CELL (2014)
The dynamic nature of the kinome
Lee M. Graves et al.
BIOCHEMICAL JOURNAL (2013)
Antimitotic drugs in cancer chemotherapy: Promises and pitfalls
Isabel Marzo et al.
BIOCHEMICAL PHARMACOLOGY (2013)
Association between BRIP1 (BACH1) polymorphisms and breast cancer risk: a meta-analysis
Noel Pabalan et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
The pre-clinical in vitro and in vivo activity of AZD6738: A potent and selective inhibitor of ATR kinase.
Sylvie M. Guichard et al.
CANCER RESEARCH (2013)
Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
Ayca Gucalp et al.
CLINICAL CANCER RESEARCH (2013)
Novel Approaches for Molecular Targeted Therapy of Breast Cancer: Interfering with PI3K/AKT/mTOR Signaling
Thomas W. Grunt et al.
CURRENT CANCER DRUG TARGETS (2013)
RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma
Pierre Tennstedt et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
An international comparison of male and female breast cancer incidence rates
Diana Ly et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Impact of PTEN Protein Expression on Benefit From Adjuvant Trastuzumab in Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the North Central Cancer Treatment Group N9831 Trial
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE
Nasim Mavaddat et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
Mechanisms of resistance to therapies targeting BRCA-mutant cancers
Christopher J. Lord et al.
NATURE MEDICINE (2013)
Small molecule induced reactivation of mutant p53 in cancer cells
Xiangrui Liu et al.
NUCLEIC ACIDS RESEARCH (2013)
Double-strand break repair by homologous recombination in primary mouse somatic cells requires BRCA1 but not the ATM kinase
Elizabeth M. Kass et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
Ron Bose et al.
CANCER DISCOVERY (2013)
The tumor suppressor gene ARHI (DIRAS3) inhibits ovarian cancer cell migration through multiple mechanisms
Zhen Lu et al.
CELL ADHESION & MIGRATION (2013)
Hereditary Breast Cancer: The Era of New Susceptibility Genes
Paraskevi Apostolou et al.
BIOMED RESEARCH INTERNATIONAL (2013)
Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort
Serena Masciari et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
High frequency of complex TP53 mutations in CNS metastases from breast cancer
C. Lo Nigro et al.
BRITISH JOURNAL OF CANCER (2012)
The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy
Remko Prevo et al.
CANCER BIOLOGY & THERAPY (2012)
Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment
Lenka Oplustilova et al.
CELL CYCLE (2012)
Animal Modeling of Cancer Pathology and Studying Tumor Response to Therapy
Simon P. Langdon
CURRENT DRUG TARGETS (2012)
Predictive in vivo animal models and translation to clinical trials
Natalie Cook et al.
DRUG DISCOVERY TODAY (2012)
Mutation screening of RAD51C in high-risk breast and ovarian cancer families
Wenping Lu et al.
FAMILIAL CANCER (2012)
Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance
Irma Kluijt et al.
FAMILIAL CANCER (2012)
Mechanisms of acquired resistance to targeted cancer therapies
Mark R. Lackner et al.
FUTURE ONCOLOGY (2012)
Predominance of pathogenic missense variants in the RAD51C gene occurring in breast and ovarian cancer families
Ana Osorio et al.
HUMAN MOLECULAR GENETICS (2012)
Analysis of RAD51C Germline Mutations in High-Risk Breast and Ovarian Cancer Families and Ovarian Cancer Patients
Ella R. Thompson et al.
HUMAN MUTATION (2012)
Inhibition of Homologous Recombination in Human Cells by Targeting RAD51 Recombinase
Fei Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Role of MRE11 in Cell Proliferation, Tumor Invasion, and DNA Repair in Breast Cancer
Shyng-Shiou F. Yuan et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
PALB2 Interacts with KEAP1 To Promote NRF2 Nuclear Accumulation and Function
Jianglin Ma et al.
MOLECULAR AND CELLULAR BIOLOGY (2012)
The BARD1 Cys557Ser variant and risk of familial breast cancer in a South-American population
Patricio Gonzalez-Hormazabal et al.
MOLECULAR BIOLOGY REPORTS (2012)
Preclinical Development of the Novel Chk1 Inhibitor SCH900776 in Combination with DNA-Damaging Agents and Antimetabolites
Ryan Montano et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models
Caroline C. Clark et al.
MOLECULAR CANCER THERAPEUTICS (2012)
The Androgen Receptor in Breast Tissues: Growth Inhibitor, Tumor Suppressor, Oncogene?
T. E. Hickey et al.
MOLECULAR ENDOCRINOLOGY (2012)
Comprehensive molecular characterization of human colon and rectal cancer
Donna M. Muzny et al.
NATURE (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Germline RAD51C mutations confer susceptibility to ovarian cancer
Chey Loveday et al.
NATURE GENETICS (2012)
Patient-derived tumour xenografts as models for oncology drug development
John J. Tentler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
RAD51 and Breast Cancer Susceptibility: No Evidence for Rare Variant Association in the Breast Cancer Family Registry Study
Florence Le Calvez-Kelm et al.
PLOS ONE (2012)
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2
Heidi Greulich et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Phosphatase and tensin homolog expression related to cetuximab effects in colorectal cancer patients: A meta-analysis
Yue Shen
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation
E. Fokas et al.
CELL DEATH & DISEASE (2012)
Genome-Wide Association Study in East Asians Identifies Novel Susceptibility Loci for Breast Cancer
Jirong Long et al.
PLOS GENETICS (2012)
Expression and clinical significance of androgen receptor in triple negative breast cancer
Xiang Luo et al.
Chinese Journal of Cancer (2012)
The ERBB network: at last, cancer therapy meets systems biology
Yosef Yarden et al.
NATURE REVIEWS CANCER (2012)
Low expression levels of ATM may substitute for CHEK2/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer
Stian Knappskog et al.
BREAST CANCER RESEARCH (2012)
The R337H mutation in TP53 and breast cancer in Brazil
Magda C. B. Gomes et al.
HEREDITARY CANCER IN CLINICAL PRACTICE (2012)
Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers
S. Park et al.
ANNALS OF ONCOLOGY (2011)
Double-Strand Break End Resection and Repair Pathway Choice
Lorraine S. Symington et al.
ANNUAL REVIEW OF GENETICS, VOL 45 (2011)
Personalized Medicine: Progress and Promise
Isaac S. Chan et al.
ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS, VOL 12 (2011)
Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel
Chun-Fang Zou et al.
BMC CANCER (2011)
Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors
Yayun Liang et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer
E. Razis et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Resistance to HER2-directed antibodies and tyrosine kinase inhibitors
Joan T. Garrett et al.
CANCER BIOLOGY & THERAPY (2011)
MRE11 Deficiency Increases Sensitivity to Poly(ADP-ribose) Polymerase Inhibition in Microsatellite Unstable Colorectal Cancers
Eduardo Vilar et al.
CANCER RESEARCH (2011)
Contribution of Inherited Mutations in the BRCA2-Interacting Protein PALB2 to Familial Breast Cancer
Silvia Casadei et al.
CANCER RESEARCH (2011)
E-Cadherin and the Cytoskeletal Network in Colorectal Cancer Development and Metastasis
Andrea Buda et al.
CELL COMMUNICATION AND ADHESION (2011)
Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women
Rong Hu et al.
CLINICAL CANCER RESEARCH (2011)
Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer
Ana M. Gonzalez-Angulo et al.
CLINICAL CANCER RESEARCH (2011)
Molecular mechanisms of tumor suppression by LKB1
Kari Vaahtomeri et al.
FEBS LETTERS (2011)
High RAD51 mRNA expression characterize estrogen receptor-positive/progesteron receptor-negative breast cancer and is associated with patient's outcome
Raffaela Barbano et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Oncoplastic Surgical Techniques for Personalized Breast Conserving Surgery in Breast Cancer Patient with Small to Moderate Sized Breast
Jung Dug Yang et al.
JOURNAL OF BREAST CANCER (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2-Overexpressing Locally Advanced Breast Cancers
Bhuvanesh Dave et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women
Muriel A. Adank et al.
JOURNAL OF MEDICAL GENETICS (2011)
Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer
Maria C. Villarroel et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Germline mutations in RAD51D confer susceptibility to ovarian cancer
Chey Loveday et al.
NATURE GENETICS (2011)
Mutations in BRIP1 confer high risk of ovarian cancer
Thorunn Rafnar et al.
NATURE GENETICS (2011)
mTOR: from growth signal integration to cancer, diabetes and ageing
Roberto Zoncu et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2011)
Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing
Tom Walsh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
RAD51 paralogs: Roles in DNA damage signalling, recombinational repair and tumorigenesis
Natsuko Suwaki et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2011)
PARP Inhibitors in BRCA Gene-Mutated Ovarian Cancer and Beyond
Susana Banerjee et al.
CURRENT ONCOLOGY REPORTS (2011)
Pathology of hereditary breast cancer
Petra van der Groep et al.
CELLULAR ONCOLOGY (2011)
Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo
Mark Barok et al.
BREAST CANCER RESEARCH (2011)
Expression of androgen receptors in primary breast cancer
S. Park et al.
ANNALS OF ONCOLOGY (2010)
The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo
Victoria J. Weston et al.
BLOOD (2010)
Association between androgen receptor gene CAG repeat polymorphism and breast cancer risk: a meta-analysis
YouJin Hao et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
PTEN status in advanced colorectal cancer treated with cetuximab
F. V. Negri et al.
BRITISH JOURNAL OF CANCER (2010)
HERC2 Is an E3 Ligase That Targets BRCA1 for Degradation
Wenwen Wu et al.
CANCER RESEARCH (2010)
Mre11-Rad50-Nbs1 conformations and the control of sensing, signaling, and effector responses at DNA double-strand breaks
Gareth J. Williams et al.
DNA REPAIR (2010)
BARD1 Homozygous Deletion, a Possible Alternative to BRCA1 Mutation in Basal Breast Cancer
Renaud Sabatier et al.
GENES CHROMOSOMES & CANCER (2010)
BARD1, a possible biomarker for breast and ovarian cancer
Irmgard Irminger-Finger
GYNECOLOGIC ONCOLOGY (2010)
Cancer Predisposing Missense and Protein Truncating BARD1 Mutations in Non-BRCA1 or BRCA2 Breast Cancer Families
Sylvia De Brakeleer et al.
HUMAN MUTATION (2010)
Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research
Rebecca C. Fitzgerald et al.
JOURNAL OF MEDICAL GENETICS (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh et al.
LANCET (2010)
ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors
Chris T. Williamson et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Role of Rad51 Down-Regulation and Extracellular Signal-Regulated Kinases 1 and 2 Inactivation in Emodin and Mitomycin C-Induced Synergistic Cytotoxicity in Human Non-Small-Cell Lung Cancer Cells
Ying-Jhen Su et al.
MOLECULAR PHARMACOLOGY (2010)
Mutation of the RAD51C gene in a Fanconi anemia-like disorder
Fiona Vaz et al.
NATURE GENETICS (2010)
Triple-negative breast cancer: disease entity or title of convenience?
Lisa Carey et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination
Remi Buisson et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2010)
Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing
Tom Walsh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features
Nadine Tung et al.
BREAST CANCER RESEARCH (2010)
Human RAD50 Deficiency in a Nijmegen Breakage Syndrome-like Disorder
Regina Waltes et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2009)
Distinct Roles of BARD1 Isoforms in Mitosis: Full-Length BARD1 Mediates Aurora B Degradation, Cancer-Associated BARD1β Scaffolds Aurora B and BRCA2
Stephan Ryser et al.
CANCER RESEARCH (2009)
Loss of Phosphatase and Tensin Homologue Deleted on Chromosome 10 Engages ErbB3 and Insulin-Like Growth Factor-I Receptor Signaling to Promote Antiestrogen Resistance in Breast Cancer
Todd W. Miller et al.
CANCER RESEARCH (2009)
High Frequency of TP53 Mutation in BRCA1 and Sporadic Basal-like Carcinomas but not in BRCA1 Luminal Breast Tumors
Elodie Manie et al.
CANCER RESEARCH (2009)
PF-00477736 Mediates Checkpoint Kinase 1 Signaling Pathway and Potentiates Docetaxel-Induced Efficacy in Xenografts
Cathy Zhang et al.
CLINICAL CANCER RESEARCH (2009)
Taking the time to make important decisions: The checkpoint effector kinases Chk1 and Chk2 and the DNA damage response
Travis H. Stracker et al.
DNA REPAIR (2009)
Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
Werner Schroth et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
The Contribution of BRCA1 and BRCA2 to Ovarian Cancer
Susan J. Ramus et al.
MOLECULAR ONCOLOGY (2009)
Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
Andrea Sartore-Bianchi et al.
PLOS ONE (2009)
PALB2 is an integral component of the BRCA complex required for homologous recombination repair
Shirley M. H. Sy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
Sian Jones et al.
SCIENCE (2009)
Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations
C. Cybulski et al.
JOURNAL OF MEDICAL GENETICS (2009)
Genetic Predisposition to Breast Cancer: Past, Present, and Future
Clare Turnbull et al.
Annual Review of Genomics and Human Genetics (2008)
Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study
L. Mellemkjaer et al.
BRITISH JOURNAL OF CANCER (2008)
Mutational analysis of thirty-two double-strand DNA break repair genes in breast and pancreatic cancers
Xianshu Wang et al.
CANCER RESEARCH (2008)
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab
Minaxi Jhawer et al.
CANCER RESEARCH (2008)
Suppression of Peutz-Jeghers polyposis by targeting mammalian target of rapamycin signaling
Chongjuan Wei et al.
CLINICAL CANCER RESEARCH (2008)
A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function
Arcangela De Nicolo et al.
CLINICAL CANCER RESEARCH (2008)
Association of common PALB2 polymorphisms with breast cancer risk:: A case-control study
Peizhan Chen et al.
CLINICAL CANCER RESEARCH (2008)
The consequences of Rad51 overexpression for normal and tumor cells
Hannah L. Klein
DNA REPAIR (2008)
Androgen receptor gene CAG repeats, estrogen exposure status, and breast cancer susceptibility
Mei-Hsuan Wu et al.
EUROPEAN JOURNAL OF CANCER PREVENTION (2008)
Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines
Pedro P. Medina et al.
HUMAN MUTATION (2008)
Postirradiation morphea: an underrecognized complication of treatment for breast cancer
Noreen Walsh et al.
HUMAN PATHOLOGY (2008)
The nuclear affairs of PTEN
Sarah M. Planchon et al.
JOURNAL OF CELL SCIENCE (2008)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene
Jirina Bartkova et al.
MOLECULAR ONCOLOGY (2008)
Molecular Origins of Cancer: Inherited Susceptibility to Common Cancers
William D. Foulkes
NEW ENGLAND JOURNAL OF MEDICINE (2008)
PTEN: a new guardian of the genome
Y. Yin et al.
ONCOGENE (2008)
CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer
Ranjan Chrisanthar et al.
PLOS ONE (2008)
Targeted rescue of a destabilized mutant of p53 by an in silico screened drug
Frank M. Boeckler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Hereditary diffuse gastric cancer: association with lobular breast cancer
Kasmintan A. Schrader et al.
FAMILIAL CANCER (2008)
Nijmegen BREAKAGE SYNDROME mutations and risk of breast cancer
Natalia Bogdanova et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
I171V germline mutation in the NBS1 gene significantly increases risk of breast cancer
Krzysztof Roznowski et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Oncogenic BARD1 isoforms expressed in gynecological cancers
Lin Li et al.
CANCER RESEARCH (2007)
RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors
Richard W. Martin et al.
CANCER RESEARCH (2007)
AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy
D. Grahame Hardie
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
A marginal regression model for multivariate failure time data with a surviving fraction
Yingwei Peng et al.
LIFETIME DATA ANALYSIS (2007)
Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome represent one condition with variable expression and age-related penetrance:: results of a clinical study of PTEN mutation carriers
K. L. Lachlan et al.
JOURNAL OF MEDICAL GENETICS (2007)
The role of ATM in breast cancer development
Jana Prokopcova et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer
David J. Hunter et al.
NATURE GENETICS (2007)
Genome-wide association study identifies novel breast cancer susceptibility loci
Douglas F. Easton et al.
NATURE (2007)
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype:: Lessons from recent developments in the IARC TP53 database
Audrey Petitjean et al.
HUMAN MUTATION (2007)
Fanconi anemia is associated with a defect in the BRCA2 partner PALB2
Bing Xia et al.
NATURE GENETICS (2007)
Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer
Sarah Reid et al.
NATURE GENETICS (2007)
PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene
Nazneen Rahman et al.
NATURE GENETICS (2007)
Enhanced expression of LKB1 in breast cancer cells attenuates angiogenesis, invasion, and metastatic potential
Zhi-Gang Zhuang et al.
MOLECULAR CANCER RESEARCH (2006)
Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles
Sheila Seal et al.
NATURE GENETICS (2006)
ATM and breast cancer susceptibility
M. Ahmed et al.
ONCOGENE (2006)
The BARD1 Cys557Ser variant and breast cancer risk in Iceland
Simon N. Stacey et al.
PLOS MEDICINE (2006)
The ATM-mediated DNA-damage response: taking shape
Yosef Shiloh
TRENDS IN BIOCHEMICAL SCIENCES (2006)
Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2
Bing Xia et al.
MOLECULAR CELL (2006)
Evaluation of RAD50 in familial breast cancer predisposition
J Tommiska et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis
JY Wu et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3)
David G. Cox et al.
BREAST CANCER RESEARCH (2006)
Interindividual variation in nucleotide excision repair genes and risk of endometrial cancer.
JM Weiss et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2005)
Cancer risks and mortality in heterozygous ATM mutation carriers
D Thompson et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
BRCA1/BARD1 inhibition of mRNA 3′ processing involves targeted degradation of RNA polymerase II
FE Kleiman et al.
GENES & DEVELOPMENT (2005)
Cancer risk according to type and location of ATM mutation in ataxia-telangiectasia families
E Cavaciuti et al.
GENES CHROMOSOMES & CANCER (2005)
Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer
AG Lewis et al.
BREAST CANCER RESEARCH (2005)
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
MC Franklin et al.
CANCER CELL (2004)
The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress
RJ Shaw et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
The LKB1 tumor suppressor negatively regulates mTOR signaling
RJ Shaw et al.
CANCER CELL (2004)
Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase
SK Rabindran et al.
CANCER RESEARCH (2004)
BRCA1-dependent ubiquitination of γ-tubulin regulates centrosome number
LM Starita et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene
J Carretero et al.
ONCOGENE (2004)
ATM variants 7271T>G and IVS10-6T>G among women with unilateral and bilateral breast cancer
JL Bernstein et al.
BRITISH JOURNAL OF CANCER (2003)
Mutational analysis of BARD1 in familial breast cancer patients in Japan
M Ishitobi et al.
CANCER LETTERS (2003)
Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals
JL Rutter et al.
HUMAN MUTATION (2003)
ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers
RZ Luo et al.
ONCOGENE (2003)
Germline TP53 mutations and Li-Fraumeni syndrome
JM Varley
HUMAN MUTATION (2003)
BARD1 participates with BRCA1 in homology-directed repair of chromosome breaks
UK Westermark et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Genomic medicine - A primer
AE Guttmacher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Male breast disease:: clinical, mammographic, and ultrasonographic features
I Günhan-Bilgen et al.
EUROPEAN JOURNAL OF RADIOLOGY (2002)
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
DB Agus et al.
CANCER CELL (2002)
The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity
R Baer et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2002)
Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families
PDP Pharoah et al.
GASTROENTEROLOGY (2001)
BRCA1 RING domain cancer-predisposing mutations - Structural consequences and effects on protein-protein interactions
PS Brzovic et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function
SB Cantor et al.
CELL (2001)
PTEN coordinates G1 arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model
LP Weng et al.
HUMAN MOLECULAR GENETICS (2001)
Cancer in patients with ataxia-telangiectasia and in their relatives in the Nordic countries
JH Olsen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression
G Berx et al.
BREAST CANCER RESEARCH (2001)
Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer
H Yu et al.
BREAST CANCER RESEARCH AND TREATMENT (2000)
Share Paper
